Aims: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV). Methods: This was a multinational, multicenter, single-blind, randomized trial in 15 centers, including 321 women. They were randomized to either vaginal DQC tablets or vaginal CLM cream. Follow-up visits were 1 week and 1 month after treatment. Clinical cure based on Amsel’s criteria was the primary outcome. Secondary outcomes were rate of treatment failures and recurrences, incidence of post-treatment vulvovaginal candidosis (VVC), lactobacillary grade (LBG), total symptom score (TSC), and safety. Results: Cure rates with DQC (C1: 81.5%, C2: 79.5%) were as high as with CLM (C1: 78.4%, C2: 77.6%). Thus, the treatment with DQC had equal efficacy as CLM cream. A trend to less common post-treatment VVC in the DQC-treated women was observed (DQC: 2.5%, CLM: 7.7%; p = 0.06). Both treatments were well tolerated with no serious adverse events occurring. Conclusion: Vaginal DQC has been shown to be equally effective as CLM cream, to be well tolerated with no systemic safety concerns, and is therefore a valid alternative therapy for women with BV [ClinicalTrials.gov, Med380104, NCT01125410].

Keywords:
Fluomizin®, Pregnancy, Bacterial vaginosis, Dequalinium chloride, Clindamycin, Vaginal infections, Local therapy
1.
Sobel JD: Vaginitis. N Engl J Med 1997;337:1896–1903.
2.
Forsum U, Holst E, Larsson PG, Vasquez A, Jakobsson T, Mattsby-Baltzer I: Bacterial vaginosis – a microbiological and immunological enigma. APMIS 2005;113:81–90.
3.
Sobel JD: Bacterial vaginosis. Annu Rev Med 2000;51:349–356.
4.
O’Brien RF: Bacterial vaginosis: many questions – any answers? Curr Opin Pediatr 2005;17:473–479.
5.
Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51:1–78.
6.
British Association for Sexual Health and HIV (BASHH), Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases): National guideline for the management of bacterial vaginosis (www.bashh.org/guidelines).
7.
Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK: High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478–1486.
8.
Larsson PG, Forsum U: Bacterial vaginosis – a disturbed bacterial flora and treatment enigma. APMIS 2005;113:305–316.
9.
Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J: Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995;41:443–449.
10.
Schmitt C, Sobel JD, Meriwether C: Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 1992;79:1020–1023.
11.
Austin MN, Beigi RH, Meyn LA, Hillier SL: Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 2005;43:4492–4497.
12.
Goldstein EJ, Citron DM, Cherubin CE, Hillier SL: Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993;31:363–372.
13.
Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT: In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother 2002;46:3995–3996.
14.
Nagaraja P: Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol 2008;26:155–157.
15.
DeBacker E, Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Temmerman M, Vaneechoutte M: Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis 2006;6:51.
16.
D’Auria FD, Simonetti G, Strippoli V: Antimicrobial characteristics of a tincture of dequalinium chloride (in Italian). Ann Ig 1989;1:1227–1241.
17.
Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G: Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung 2002;52:699–705.
18.
Hugo WB, Frier M: Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol 1969;17:118–127.
19.
Petersen EE, Weissenbacher ER, Hengst P, Spitzbart H, Weise W, Wolff F, Dreher E, Ernst U, Della Casa V, Pohlig G, Graf F, Kaiser RR: Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung 2002;52:706–715.
20.
Strecker M, Kokemohr H, Teucher T, Schmitz H: Antiseptika gegen Vulvovaginitiden. TW Gynäkol 1993;6:409–412.
21.
Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach DA, Holmes KK: Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiological associations. Am J Med 1983;74:14–22.
22.
Donders GG, Vereecken A, Dekeersmaecker A, van Bulck B, Spitz B: Wet mount microscopy reflects functional vaginal lactobacillary flora better than Gram stain. J Clin Pathol 2000;53:308–313.
23.
Bauer P, Köhne K: Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029–1041.
24.
Farrington CP, Manning G: Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stad Med 1990;9:1447–1454.
25.
Mann H, Whitney D: On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist 1947;50–60.
26.
Donders GG: Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 2007;21:355–373.
27.
Koumans EH, Markowitz LE, Hogan V: Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002;35:S152–S172.
28.
Agnew KJ, Hillier SL: The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis 1995;22:269–273.
29.
Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S: Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 2008;8:3.
30.
Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G: The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005;112:234–240.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.